Clinical study of treatment of 112 chronic hepatitis B patients with Peginterferon α-2a and Jiedushengbai granule
10.3760/cma.j.issn.1003-9279.2012.03.019
- VernacularTitle:派罗欣联合解毒升白颗粒治疗慢性乙型肝炎112例临床研究
- Author:
Min XIE
1
;
Qian GAO
;
Xing-Hua TAN
;
Ai-Ming ZHANG
;
Keng CHEN
;
Hui-Jun MAO
;
Hui-Min FAN
;
Chun-Liang LEI
Author Information
1. 广州市第八人民医院
- Keywords:
Hepatitis B,chronic;
Treatment outcome;
Interferon alfa-2a
- From:
Chinese Journal of Experimental and Clinical Virology
2012;26(3):221-224
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical effects and adverse reactions of Peginterferon α-2a in combination with Jiedushengbai granule in the treatment of patients with chronic hepatitis B.Methods 112 patients with chronic hepatitis B who were suitable for treatment of interferon were selected and divided into study group and control group,and each group had 56 patients.The study group received Peginterferon α-2a in combination with Jiedushengbai granule and the control group was treated with Peginterferon α-2a alone.The score of Chinese traditional medicine symptoms,rate of negative conversion of HBeAg and HBV DNA,conversion of HBeAg/anti-HBe at the 12th,24th,36th,48th week after treatment and the 24th week after completion of medication were recorded and compared between the two groups.Results 48 weeks after drug administration the symptoms of patients in the study group (overall response rate 96.4％ ) were significantly improved compared with the control group ( overall response rate 85.7％ ).Rate of negative conversion of HBeAg and HBV DNA,conversion of HBeAg/anti-HBe at the 48th week after treatment in the study group were 54.8％,48.4％ and 62.5％,significantly higher than those in the control group(28.1％,21.9％ and 42.9％,P ＜ 0.05). The serum adverse reactions in the study group were 89 events,significantly fewer than those in the control group( 165 events,P ＜ 0.05 ).Conclusion Peginterferon α-2a in combination with Jiedushengbai granule could improve the clinical symptoms and clinical effects and reduce adverse reactions related to Peginterferon α-2a.
